Multichannel tDCS with Advanced Targeting for Major Depressive Disorder: A Tele-Supervised At-Home Pilot Study

Area of Science:

• Neuroscience
• Psychiatry
• Medical Devices

Background:

• Major Depressive Disorder (MDD) is a leading cause of disability worldwide.
• Transcranial direct current stimulation (tDCS) shows promise for treating MDD, but in-clinic administration can be a barrier.
• Remote, at-home tDCS offers a potential solution to improve accessibility.

Approach:

• This study evaluated remotely supervised, multichannel tDCS administered at home for patients with MDD.
• Participants (N=34) received 37 sessions over 8 weeks, with assessments using the Montgomery-Asberg Depression Rating Scale (MADRS).
• The protocol focused on feasibility, safety, and exploratory efficacy, using computational models for optimal electrode placement.

Key Points:

• High compliance (85% completed all sessions) and no adverse events were reported, demonstrating safety and feasibility.
• A significant median MADRS score reduction of 64.5% was observed 4 weeks post-treatment.
• A 72.7% response rate (≥50% MADRS improvement) was achieved, indicating substantial antidepressant effects.

Conclusions:

• Remotely supervised, multichannel home-based tDCS is a safe and feasible treatment for MDD.
• The observed antidepressant efficacy warrants further investigation in controlled clinical trials.
• This approach may enhance treatment accessibility for individuals with major depressive disorder.